Bedrijfsoverzicht
Editas Medicine, Inc. is a clinical stage genome editing company dedicated to developing transformative genomic medicines for a variety of serious diseases. The enterprise utilizes a proprietary gene editing platform built upon CRISPR technology to create one-time therapies, positioning itself within the competitive landscape of genetic medicine. Operating within the healthcare sector and the biotechnology industry, the company focuses on high-risk, high-reward research and development phases typical of early-stage life science firms. The entity currently holds a market capitalization of $287.74M and generates annual revenue of $40.52M while employing a workforce of 87 individuals. These financial metrics indicate that the company operates with a relatively small market cap compared to established pharmaceutical giants, reflecting its status as a capital-intensive firm heavily invested in R&D rather than commercial scale. The revenue figure, standing at $40.52M, suggests limited commercial product sales to date, which is consistent with the development stage of its lead programs and the typical lifecycle of a biotechnology firm still navigating clinical trials.
Financiële gezondheid
The company reported revenue of $40.52M, a net income of $-160,060,000, and an EBITDA of $-94,059,000 for the trailing twelve months. The substantial gap between the positive revenue of $40.52M and the deeply negative net income reveals an aggressive cost structure where operating expenses, likely dominated by research and development and clinical trial costs, far exceed current sales income. Free cash flow stands at $-71,477,872, indicating that the company is burning cash rapidly to fund its operations and development pipeline, which constrains immediate financial flexibility without external capital raises. The gross margin is reported as -122.0%, an anomaly often seen in early-stage biotech firms where sales are nominal but fixed costs are high, while the operating margin sits at -56.7% and the profit margin at 0.0%, further illustrating the heavy burden of overhead costs relative to current revenue generation. Total cash reserves amount to $146.64M, which significantly exceeds the total debt of $18.10M, yet the balance sheet is leveraged with a debt-to-equity ratio of 66.34, reflecting a capital structure that relies heavily on equity financing given the negative earnings. The current ratio of 3.54 indicates a strong short-term liquidity position, as current assets are more than three times the value of current liabilities, providing a buffer for ongoing operational needs. Return on equity is -198.1% and return on assets is -23.5%, metrics that reveal management is currently utilizing shareholder and asset bases to generate losses rather than profits, a common characteristic during the pre-revenue or early commercialization phases of biotechnology companies.
Waarderingsbeoordeling
Trailing twelve-month P/E is N/A due to negative earnings, while the forward P/E is -3.41, implying that the market currently prices the stock based on future expectations rather than historical profitability. The price-to-book ratio is 10.54, indicating that the market values the company at a significant premium over its book value, likely reflecting the high value placed on its intellectual property and pipeline potential despite current losses. The price-to-sales ratio is 7.10 and the EV/EBITDA is -1.69, suggesting that investors are willing to pay a high multiple for every dollar of revenue, anticipating future commercialization success from its genomic medicine portfolio. The 52-week high is $4.54 and the 52-week low is $1.18, meaning the stock has experienced extreme volatility within this trading range over the past year. The beta value is 2.04, which indicates that the stock's price volatility is more than double that of the broader market, exposing investors to significant systemic risk and sharp price swings during periods of market uncertainty. These alternative valuation metrics highlight the speculative nature of the investment, where traditional profitability measures like P/E are not applicable, and value is derived entirely from the perceived potential of future clinical outcomes and regulatory approvals.
Growth & Income
Revenue growth year-over-year is -19.2% and earnings growth is N/A, indicating that the company is currently contracting in terms of top-line sales rather than expanding its commercial footprint. Since the earnings growth is not calculable due to negative earnings, the negative revenue growth suggests that the company is not yet achieving the scale required to offset its high fixed costs, a typical challenge for firms transitioning from clinical trials to commercial product launches. As a non-dividend payer, the company does not distribute a dividend yield or operates with a 0.0% payout ratio, meaning all available resources are theoretically available for reinvestment into growth initiatives rather than shareholder distributions. The overall growth and income profile is characterized by negative revenue expansion and a complete absence of dividend income, reflecting a classic capital-allocator strategy where investors accept current losses in exchange for potential future value creation from the company's gene editing platform.